Published in Front Immunol on July 23, 2014
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer | NCT00514072
Expression and Polymorphism of Toll-Like Receptor 4 and Effect on NF-κB Mediated Inflammation in Colon Cancer Patients. PLoS One (2016) 0.83
Pattern Recognition Receptors in Cancer Progression and Metastasis. Cancer Growth Metastasis (2015) 0.82
Association between toll-like receptors 9 (TLR9) gene polymorphism and risk of pulmonary tuberculosis: meta-analysis. BMC Pulm Med (2015) 0.80
European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol (2017) 0.77
Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine (Baltimore) (2016) 0.77
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier. BMC Cancer (2016) 0.75
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int J Mol Sci (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 37.15
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 25.15
Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 19.15
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 14.24
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol (1989) 12.08
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
MicroRNAs in Cancer. Annu Rev Med (2009) 9.37
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science (1999) 7.75
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 7.38
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science (2007) 4.90
Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem (2007) 4.56
MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol (2011) 4.00
Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 3.35
MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev (2009) 3.25
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev (2009) 2.30
Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol (2005) 2.05
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol (2011) 1.86
A trio of microRNAs that control Toll-like receptor signalling. Int Immunol (2011) 1.79
Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res (2005) 1.77
Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst (2005) 1.55
Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis (2008) 1.48
Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate (2009) 1.45
Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3. PLoS One (2011) 1.41
Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate (2007) 1.37
Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol (2007) 1.32
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer (2008) 1.25
Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res (2011) 1.23
Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res (2010) 1.21
Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol (2009) 1.19
Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.17
Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother (2010) 1.14
MicroRNAs: new regulators of Toll-like receptor signalling pathways. Biomed Res Int (2014) 1.11
Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate (2010) 1.08
Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia (2010) 1.07
Success of HPV vaccination is now a matter of coverage. Lancet Oncol (2011) 1.04
The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet (2009) 1.01
Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells. Mol Biol Rep (2009) 0.99
TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol (2010) 0.98
Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol (2007) 0.97
Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother (2011) 0.97
TLR4 signaling promotes the expression of VEGF and TGFbeta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cell Immunol (2008) 0.96
Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate (2009) 0.96
Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation. J Leukoc Biol (2006) 0.95
Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression. Proc Natl Acad Sci U S A (2013) 0.92
Sequence variants of Toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol (2011) 0.90
Clinical studies with ampligen (mismatched double-stranded RNA). J Biol Response Mod (1985) 0.88
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother (2013) 0.86
Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate (2011) 0.85
How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology (2012) 0.83
Toll-like receptor 4 in rat prostate: modulation by testosterone and acute bacterial infection in epithelial and stromal cells. Biol Reprod (2006) 0.82
In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod. Int J Oncol (2013) 0.81
Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells. Cell Biol Toxicol (2012) 0.81
Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. Oncol Rep (2013) 0.80
Are Toll-like receptor gene polymorphisms associated with prostate cancer? Cancer Manag Res (2012) 0.80
TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells. Am J Reprod Immunol (2013) 0.79
Effects of a human compact anti-ErbB2 antibody on prostate cancer. Oncol Rep (2012) 0.79
Is there room for combined modality treatments? Dosimetric comparison of boost strategies for advanced head and neck and prostate cancer. J Radiat Res (2013) 0.77